{'fraction_non_alphanumeric': 0.04142011834319527, 'fraction_numerical': 0.019970414201183433, 'mean_word_length': 5.122171945701357, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Short Children Born Prematurely: Data from KIGS

Background: Advances in neonatal care have enabled the survival of extremely preterm infants. Some of them have growth failure and remain short at later ages. As a consequence, children born prematurely may be candidates for growth hormone (GH) treatment. Aims: The goal of this study was to obtain information about children on GH therapy enrolled in the Pfizer International Growth Database (KIGS) who were born prematurely. Patients: The KIGS database was queried for data on prepubertal short children (height <–2 standard deviation score; SDS) born with gestational age below 37 weeks. Birth weight had to be available. Results: In total, 3,215 patients were selected and classified according to gestational age and birth weight as preterm (<37 weeks’ gestation), very preterm (VP; <33 weeks’ gestation), appropriate for gestational age (AGA; birth weight between –2 and +2 SDS) or small for gestational age (SGA; birth weight <–2 SDS). Of these, 1,928 children were preterm AGA, 629 very preterm AGA, 519 preterm SGA, and 139 very preterm SGA. Conclusions: KIGS is a cumulative database and provides a unique opportunity to evaluate the growth response to GH therapy of premature children born with differences in gestational ages, size at birth, rate of postnatal growth, and GH secretion status.